First Episode and Recurrent Venous Thromboembolism: Who is Identifiably at Risk?

Fowkes, 2003, Incidence of diagnosed deep vein thrombosis in the general population: systematic review, Eur J Vasc Endovasc Surg, 25, 1, 10.1053/ejvs.2002.1778 Naess, 2007, Incidence and mortality of venous thrombosis: a population based study, J Thromb Haemost, 5, 692, 10.1111/j.1538-7836.2007.02450.x Heit, 2006, The epidemiology of venous thromboembolism in the community: implications for prevention and management, J Thromb Thrombolysis, 21, 23, 10.1007/s11239-006-5572-y Rosendaal, 1999, Risk factors for venous thrombotic disease, Thromb Haemost, 82 Cushman, 2004, Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology, Am J Med, 117, 19, 10.1016/j.amjmed.2004.01.018 Cushman, 2004, Estrogen plus progestin and risk of venous thrombosis, JAMA, 292, 1573, 10.1001/jama.292.13.1573 Keijzer, 2007, No interaction between factor V Leiden and hyperhomocysteinemia or MTHFR 677TT genotype in venous thrombosis, Thromb Haemost, 97, 32, 10.1160/TH06-09-0486 Ageno, 2008, Cardiovascular risk factors and venous thromboembolism: a meta-analysis, Circulation, 117, 93, 10.1161/CIRCULATIONAHA.107.709204 White, 1998, Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California, Ann Intern Med, 128, 737, 10.7326/0003-4819-128-9-199805010-00006 Bezemer, 2008, Gene variants associated with deep vein thrombosis, JAMA, 299, 1306, 10.1001/jama.299.11.1306 Wells, 1997, Value of assessment of pretest probability of deep-vein thrombosis in clinical management, Lancet, 350, 1795, 10.1016/S0140-6736(97)08140-3 Cushman, 2005, Inherited risk factors for venous thrombosis, Hematology, 2005, 452, 10.1182/asheducation-2005.1.452 Douketis, 2000, Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy, Arch Intern Med, 160, 3431, 10.1001/archinte.160.22.3431 Hansson, 2000, Recurrent venous thromboembolism after deep venous thrombosis, Arch Intern Med, 160, 769, 10.1001/archinte.160.6.769 Prandoni, 2007, The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism, Haematologica, 92, 199, 10.3324/haematol.10516 Marchiori, 2007, The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation, Haematologica, 92, 1107, 10.3324/haematol.10234 Christiansen, 2005, Thrombophilia, clinical factors, and recurrent venous thrombotic events, JAMA, 293, 2352, 10.1001/jama.293.19.2352 Kyrle, 2004, The risk of recurrent venous thromboembolism in men and women, N Engl J Med, 350, 2558, 10.1056/NEJMoa032959 Levi, 2006, Commentary: male sex, first idiopathic deep venous thrombosis, and oral contraception were risk factors for recurrent venous thrombotic events, Evid Based Med, 11, 59, 10.1136/ebm.11.2.59 Prandoni, 2002, Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism, Ann Intern Med, 137, 955, 10.7326/0003-4819-137-12-200212170-00008 Palareti, 2003, Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia, Circulation, 108, 313, 10.1161/01.CIR.0000079162.69615.0F Palareti, 2006, D-dimer testing to determine the duration of anticoagulant therapy, N Engl J Med, 355, 1780, 10.1056/NEJMoa054444 Heit, 2000, Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study, Arch Intern Med, 160, 761, 10.1001/archinte.160.6.761 Schulman, 1998, Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy, Am J Med, 104, 332, 10.1016/S0002-9343(98)00060-6 van den Belt, 1997, Recurrence of venous thromboembolism in patients with familial thrombophilia, Arch Intern Med, 157, 227, 10.1001/archinte.157.19.2227 Büller, 2004, Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest, 126, 401S, 10.1378/chest.126.3_suppl.401S Kearon, 2006, Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism, JAMA, 296, 935, 10.1001/jama.296.8.935 Warkentin, 1995, Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin, N Engl J Med, 332, 1330, 10.1056/NEJM199505183322003 Segal, 2007, Management of venous thromboembolism: a systematic review for a practice guideline, Ann Intern Med, 146, 211, 10.7326/0003-4819-146-3-200702060-00150 Akl, 2008, Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer, Cochrane Database Syst Rev. Büller, 2004, Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis, Ann Intern Med, 140, 867, 10.7326/0003-4819-140-11-200406010-00007 Büller, 2003, Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism, N Engl J Med, 349, 1695, 10.1056/NEJMoa035451 Schulman, 1995, A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism, N Engl J Med, 332, 1661, 10.1056/NEJM199506223322501 1992, Optimal duration of anticoagulation for deep vein thrombosis and pulmonary embolism, Lancet, 340, 873, 10.1016/0140-6736(92)93285-U Levine, 1995, Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis, Thromb Haemost, 74, 606, 10.1055/s-0038-1649783 Kearon, 1999, A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism, N Engl J Med, 340, 901, 10.1056/NEJM199903253401201 Agnelli, 2001, Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis, N Engl J Med, 345, 165, 10.1056/NEJM200107193450302 Ridker, 2003, Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism, N Engl J Med, 348, 1425, 10.1056/NEJMoa035029 Kearon, 2003, Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism, N Engl J Med, 349, 631, 10.1056/NEJMoa035422 Ost, 2005, Duration of anticoagulation following venous thromboembolism: a meta-analysis, JAMA, 294, 706, 10.1001/jama.294.6.706 Lee, 2003, Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer, N Engl J Med, 349, 146, 10.1056/NEJMoa025313 Lee, 2008, Cancer and venous thromboembolism: prevention, treatment, and survival, J Thromb Thrombolysis, 25, 33, 10.1007/s11239-007-0102-0 Akl, 2008, Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer, Cochrane Database Syst Rev Pinede, 2001, Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis, Circulation, 103, 2453, 10.1161/01.CIR.103.20.2453 Gillet, 2007, Short-term and mid-term outcome of isolated symptomatic muscular valf vein thrombosis, J Vasc Surg, 46, 513, 10.1016/j.jvs.2007.04.040 Wheeler, 2008, Abstract, Annual Meeting of the Society for Vascular Surgery Schwarz, 2001, Therapy of isolated calf muscle vein thrombosis with low-molecular-weight heparin, Blood Coagul Fibrinolysis, 12, 597, 10.1097/00001721-200110000-00014